Extracellular vesicles as a next-generation drug delivery platform in a more physiological MPS based microenvironment

Tumor metastases represent the main cause of mortality in neoplastic patients. Current therapeutic protocols target cancer cells, but the damage of normal cells and tissues is the main unsolved hurdle. Therefore, the development of innovative targeted therapeutic strategies with minimal side effects and systemic toxicity represents the future clinical challenge.
The role of the extracellular matrix (ECM) in tumor growth and progression is gaining growing interest and its investigation may allow to identify unique markers specifically targeting cancer tissues.
Among novel targeting strategies, extracellular vescicles (EVs) emerged as next-generation drug delivery platforms. EVs have an intrinsic tissue-homing capability, harnessing specific barcodes to find their target both locally and systemically.

• • • Conference:
    • Authors: R. Tasso¹, E. Palama³, MC. Ciferri¹, N. Rosenwasser¹, R. Quarto¹, M. Aiello^2,3, S. Scaglione^2,3